Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I.
about
Liver tumors in children with metabolic disordersDevelopment of humanized mouse models to study human malaria parasite infectionCell therapy for the diseased liver: from stem cell biology to novel models for hepatotropic human pathogensNew horizons for studying human hepatotropic infectionsMechanistic inferences from the crystal structure of fumarylacetoacetate hydrolase with a bound phosphorus-based inhibitorComplete rescue of lethal albino c14CoS mice by null mutation of 4-hydroxyphenylpyruvate dioxygenase and induction of apoptosis of hepatocytes in these mice by in vivo retrieval of the tyrosine catabolic pathwayLiver repopulation and correction of metabolic liver disease by transplanted adult mouse pancreatic cellsA universal system to select gene-modified hepatocytes in vivoGeneration of healthy mice from gene-corrected disease-specific induced pluripotent stem cellsChimeric mouse model for the infection of hepatitis B and C virusesComplete Plasmodium falciparum liver-stage development in liver-chimeric mice.Ploidy reductions in murine fusion-derived hepatocytes.Who needs a liver transplant? (new disease specific indications).Non-viral FoxM1 gene delivery to hepatocytes enhances liver repopulation.Hepatocyte nuclear factor-1 as marker of epithelial phenotype reveals marrow-derived hepatocytes, but not duct cells, after liver injury in mice.Hippo pathway activity influences liver cell fate.Liver xeno-repopulation with human hepatocytes in Fah-/-Rag2-/- mice after pharmacological immunosuppression.Induced pluripotent stem cell-derived hepatocytes have the functional and proliferative capabilities needed for liver regeneration in mice.Bone marrow transplantation concurrently reconstitutes donor liver and immune system across host species barrier in miceInduction of functional hepatocyte-like cells from mouse fibroblasts by defined factors.Maleylacetoacetate isomerase (MAAI/GSTZ)-deficient mice reveal a glutathione-dependent nonenzymatic bypass in tyrosine catabolism.Sustained phosphorylation of Bid is a marker for resistance to Fas-induced apoptosis during chronic liver diseases.Rescue of lethal hepatic failure by hepatized lymph nodes in mice.Mechanisms of liver injury relevant to pediatric hepatology.The origin and liver repopulating capacity of murine oval cells.Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1.Broadly neutralizing antibodies abrogate established hepatitis C virus infectionHuman cord blood stem cells generate human cytokeratin 18-negative hepatocyte-like cells in injured mouse liver.Adeno-associated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivo.Efficient production of Fah-null heterozygote pigs by chimeric adeno-associated virus-mediated gene knockout and somatic cell nuclear transfer.In vivo suppressor mutations correct a murine model of hereditary tyrosinemia type I.Bone marrow-derived hepatocytes : rare but promising.Kinetics of liver repopulation after bone marrow transplantation.Serial transplantation reveals the stem-cell-like regenerative potential of adult mouse hepatocytesThe repopulation potential of hepatocyte populations differing in size and prior mitotic expansion.Hepatocyte transplantation into diseased mouse liver. Kinetics of parenchymal repopulation and identification of the proliferative capacity of tetraploid and octaploid hepatocytesHybrid Periportal Hepatocytes Regenerate the Injured Liver without Giving Rise to Cancer.Natural Killer Cells-Produced IFN-γ Improves Bone Marrow-Derived Hepatocytes Regeneration in Murine Liver Failure Model.AAV-mediated gene targeting is significantly enhanced by transient inhibition of nonhomologous end joining or the proteasome in vivoRobust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice
P2860
Q26770292-530CF068-2520-4BD0-B0B8-0C98A3E7B634Q26851983-98E6999F-6316-4F28-BC7A-1F07FF7A1BCFQ27487009-F675E7D4-B401-4A0F-BB55-B60016A4787CQ27490975-7A4B19B3-6B1D-417D-8E6C-1C0549EA9AC6Q27629252-5D1D8495-E92C-4397-AFCD-A540EB963012Q28119001-EBEFDA68-98D1-4751-B611-827E15DC6614Q28346158-D655AAA1-A7A9-442D-8E71-C2249F20B08DQ28468539-86D2BC32-5102-4048-9A1C-D7F695CA5C04Q28478987-45AD7133-3D3A-48D0-B471-3BDC3B6D9ADDQ28534370-C64158E4-C379-47E8-91CC-10536833EC19Q30525395-1ABF0979-D572-49B6-AF29-72C739DA00C6Q33410782-F59B7514-2577-4259-8AB9-3E182E0569B0Q33588074-1000ADBD-C78D-4956-9C7D-D4FD72203A42Q33720308-5DB90FF4-6E7E-443F-A340-0AE6A58D746EQ33756841-F289988D-6D34-44FD-B820-4E136206F7CCQ34060093-907F965D-109B-436E-8AB0-A94F1CB67B27Q34086937-3E770B33-150B-49C0-8FA6-767C1E1A90E5Q34090220-8E5F0147-8F07-46D8-BEE0-4FC1CE791E78Q34142453-78190768-5FD7-4B59-9A89-83EFBB316607Q34184375-6F05C72E-D32C-4671-9CCC-5B4201C6DADEQ34283083-18D36BBD-D8B6-4AE9-97B1-5678B1F60B2DQ34504973-A8A1BC1D-6016-40ED-8393-0E38B153A257Q34543378-53CB8EF1-E88A-4F91-AE4E-75958FE5F0F4Q34559789-CBC8B6F7-CB1E-405D-A023-A82FBA1A98E5Q34582398-71CE679F-3062-49D3-BD1F-739C7A9D5175Q34590786-D181904A-EC8C-4298-8577-9B7C467B0D90Q35032263-B1711873-F643-4FBE-A7D0-B6C8CB64CD70Q35085099-DAFDD657-08EE-429A-A102-466EB6BF2F6FQ35105022-F33C6232-2E62-4DED-918A-4ECED497CA65Q35249273-3F030455-5BB9-4C78-84A6-B889F7002701Q35723184-A8E4844A-32B6-4502-864C-D5DF32A95A5EQ35747548-75C9253A-8674-4038-A22F-CF947D37AD21Q35747636-3EE1142B-6241-48F4-BB79-B6A47F257ECEQ35764088-CAAE15CF-E3DB-4A12-81EA-A0006C65B069Q35787953-436411EB-B3F9-410E-B39C-23CAEB82319EQ35829671-AF167D0F-52BB-45DE-9F6F-ADA69CCDB1E6Q35985007-7658AD4D-73DB-42BD-96F4-7F45EB36AF85Q36033943-57E5FCFB-7529-4D56-AD66-A94A79A30A49Q36084471-E6C381BD-2DAB-4519-978C-0D73EEC8B01DQ36115197-5FEB162E-F23C-4D5A-B294-B37BFD84004A
P2860
Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh-hant
name
Pharmacological correction of ...... ereditary tyrosinaemia type I.
@en
Pharmacological correction of ...... ereditary tyrosinaemia type I.
@nl
type
label
Pharmacological correction of ...... ereditary tyrosinaemia type I.
@en
Pharmacological correction of ...... ereditary tyrosinaemia type I.
@nl
prefLabel
Pharmacological correction of ...... ereditary tyrosinaemia type I.
@en
Pharmacological correction of ...... ereditary tyrosinaemia type I.
@nl
P2093
P2860
P356
P1433
P1476
Pharmacological correction of ...... ereditary tyrosinaemia type I.
@en
P2093
Finegold M
Kennaway NG
Lindstedt S
Papaconstantinou J
Torres-Ramos CA
al-Dhalimy M
P2860
P2888
P304
P356
10.1038/NG0895-453
P407
P577
1995-08-01T00:00:00Z
P6179
1044553748